近期事件 2026年2月9日，公司向美国FDA和欧洲EMA提交乌帕替尼(RINVOQ)用于治疗成人和青少年非节段型白 癜风的新适应症申请。若获批，该药将成为全球首个治疗白癜风的全身性药物。 业绩经营情况 经济观察网艾伯维公司(ABBV.N)股票在2026年2月12日上涨2.99%(收盘价227.50美元)，主要受以下因素 驱动： 2026年2月5日，多家华尔街机构更新评级，如TD Cowen维持"买入"评级(目标价280美元)，瑞士银行维 持"持有"评级(目标价230美元)。当前25家机构目标均价为251.52美元，较2月12日收盘价存在上行空 间。 市场环境 同日制药板块上涨1.87%，道琼斯指数下跌1.34%，资金向业绩稳健的医药股轮动。公司股息率2.92%也 吸引部分稳健型资金关注。 以上内容基于公开资料整理，不构成投资建议。 2月6日公布的2025年全年财报显示，营收达611.60亿美元，同比增长8.6%，其中乌帕替尼全球销售额 83.04亿美元(同比增长39.1%)，免疫学业务营收304亿美元(同比增长14%)。 机构观点 ...

Core Viewpoint - China National Pharmaceutical Group (国药控股) shares have risen over 3%, reaching a new high of 20.86 HKD this year, driven by positive market sentiment and analyst recommendations [1] Group 1: Stock Performance - As of the report, the stock price increased by 3.49%, trading at 20.78 HKD with a transaction volume of 111.2 million HKD [1] - The stock has been positively influenced by a report from Morgan Stanley, which predicts a 70% to 80% chance of price increase within the next 30 days, with a target price set at 22.5 HKD [1] Group 2: Company Performance - Morgan Stanley noted that despite weak domestic demand and ongoing technology licensing activities in China, the pharmaceutical distributor is expected to gain attention by 2025 [1] - The company is currently viewed as a good entry point based on a projected price-to-earnings ratio of 6.5 times for 2026 [1] Group 3: Subsidiary Performance - Two subsidiaries of China National Pharmaceutical Group reported third-quarter results showing positive trends, contributing to the overall group performance [1] - China National Pharmaceutical Co., as a distributor in Beijing and a major supplier of anesthetics, reported a year-on-year revenue and profit increase of 4% and 13%, respectively [1] - China National Pharmaceutical's subsidiary, which manages the southern distribution network and the Guoda Pharmacy chain, experienced a year-on-year revenue and net profit decline of 2% and 10%, but indicated that the distribution business is stabilizing and returning to growth [1]

Core Viewpoint - The article discusses the recent investment actions of Feng Liu, highlighting a new position in a pharmaceutical stock, indicating a strategic shift or opportunity in the healthcare sector [1] Group 1: Investment Actions - Feng Liu has recently entered a new position in a pharmaceutical company, suggesting a bullish outlook on the sector [1] - The article emphasizes the evolution of ETFs and their growing importance in investment strategies, particularly in the healthcare industry [1] Group 2: Market Trends - There is a notable trend in the pharmaceutical sector, with increasing interest from institutional investors, which may signal potential growth opportunities [1] - The article points out the performance metrics of the pharmaceutical stock, indicating a positive trajectory that aligns with broader market trends [1]

医药股遭遇"至暗时刻"。 此举进一步加剧了医药板块的抛售压力，使得已经表现不佳的医药股在今年的处境更加艰难。 做多机会与政策风险并存 James同时表示，尽管医药股的走势看起来像"正在下落的刀"，但随着许多医药股价接近其交易区间底 部，现在可能是"咬紧牙关，增加医药股净头寸"的时候了。 高盛数据显示，从市场定位来看，欧盟医药板块多空比率接近5年低点，而美国市场在空头方面甚至更 加极端——这种极端定位通常为反弹奠定基础。 根据高盛欧洲医药专家Seth James的分析，当前医药股的交易表现宛如"ESG时代巅峰时期的能源股—— 仿佛正在消亡"。 数据显示，该板块相对市盈率已降至自全球金融危机复苏期和新冠疫情高峰期以来的最低水平；相对标 普500指数的估值已降至历史新低，创下有记录以来的最大折价。 James指出： "令人震惊的是，该板块目前的交易折价甚至超过了过去任何政策不确定性的高峰期。" 据媒体报道，周一，美国总统特朗普签署一项行政命令，以把美国国内药品价格降至与药价最低的国家 相同的水平。他预计，美国处方药和药品价格将因此降低59%至90%。 高盛分析师Asad Haider指出，上述因素尽管可能最终成为" ...